Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
about
Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment.Pemetrexed for previously treated patients with non-small cell lung cancer and differences in efficacy according to thymidylate synthase expression.A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001).The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapyThe Efficacy and Safety of Platinum/Vinorelbine as More Than Second-Line Chemotherapy for Advanced Non-small Cell Lung Cancer.Synchronous lung and gastric cancers successfully treated with carboplatin and pemetrexed: a case report.Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cellsInterstitial Pneumonitis after Treatment with Pemetrexed for Non-small Cell Lung CancerPost-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.Maintenance therapy for metastatic non-small-cell lung cancer - the role of pemetrexedPemetrexed induced pneumonitis.Salvage treatment with apatinib for advanced non-small-cell lung cancer.Pemetrexed in heavily pretreated non-small-cell lung cancer patients: case report and review of the literature.Third- and further-line therapy in advanced non-small-cell lung cancer patients: an overview.Third-line therapy for advanced non-small-cell lung cancer patients: feasible drugs for feasible patients.Pemetrexed in previously treated non-small cell lung cancer patients with poor performance status.[Analysis of the efficacy and survival of third-line treatment in advanced non-small cell lung cancer].[Efficacy of pemetrexed as second-line therapy or beyond in patients with advanced non-small cell lung cancer].Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis.
P2860
Q33399863-BC86F349-865F-4D05-8223-3D2133805098Q33404332-E7437029-674A-4909-9A3C-BD06BB14BFF1Q33411038-D67B4754-1467-4B5E-BFD6-4FAA5EA8D541Q33655128-9759E80D-4D37-46EC-A67C-FC51343EE6ADQ36186958-22309BCB-3D6F-4AC1-9A63-B2C43B4D2928Q36233013-BE956716-71BF-4102-A4C5-CBB9837F9C85Q36557343-FDE7F47D-9F31-49D8-8C2F-ECF6DBD78BFCQ36775137-FE50DB1B-1AD7-46C2-83E3-22EE455FD07EQ37329579-0A14C0BE-E615-4ADF-8149-308F187DB3EEQ37645165-47A88B61-BF05-4241-B763-2F5BB6D2E685Q37694446-AE754E24-105A-47EF-A302-3B165E50924EQ37725637-790966DC-1C9D-4A42-863C-BD64271EEDFFQ37818301-933C195B-3B0E-45A7-AB1B-041CC893FC78Q38268170-A460DC48-A0FA-4FA3-8FCC-AE847F74894AQ39276079-6A3E6C93-2CD5-4EDA-B4CF-5CD3D3C60339Q53443476-9DCCA3D4-9784-4C09-9624-FB0450B9FB7DQ54505622-B7270C3A-8BDC-4538-93E7-C3602BB08D80Q55425816-FD0E1D2C-D5EA-480F-BCAF-F195A396E4EFQ55484524-963B94D0-03B0-4DF0-9548-171B3B96AF0D
P2860
Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Efficacy and toxicity of pemet ...... or non-small cell lung cancer.
@en
Efficacy and toxicity of pemet ...... or non-small cell lung cancer.
@nl
type
label
Efficacy and toxicity of pemet ...... or non-small cell lung cancer.
@en
Efficacy and toxicity of pemet ...... or non-small cell lung cancer.
@nl
prefLabel
Efficacy and toxicity of pemet ...... or non-small cell lung cancer.
@en
Efficacy and toxicity of pemet ...... or non-small cell lung cancer.
@nl
P2093
P356
P1476
Efficacy and toxicity of pemet ...... or non-small cell lung cancer.
@en
P2093
Choon-Taek Lee
Ho Il Yoon
Jae-Ho Lee
Jee Hyun Kim
Jong Seok Lee
Jong-Mu Sun
Keun-Wook Lee
Yu Jung Kim
P356
10.1093/JJCO/HYN118
P577
2008-10-24T00:00:00Z